Theratechnologies Inc T.TH

Sortina Pharma - more signs Sort1 as marker for brain cancer

[Wino115]

The Swedish group, pursuing the stem cell disruptive approach to stopping cancers overexpressing sort1, has extended their research to show it's also a useful biomarker and possibly a therapeutic target for a form of brain cancer.  Always a bit trickier cancer.  Their pre-clinical research followed a similar tissue sample study as THTX and other reseachers have done over the last few years showing sort1 overexpression and how it progresses with the stage of the cancer.  More highlighting of the target as highly prospective for therapies is a positive.

The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma

https://pubmed.ncbi.nlm.nih.gov/37173980/

[scarlet1967]

"In conclusion, the present study points to sortilin as a new potential clinical biomarker for predicting GBM aggressiveness and patient survival. In addition, targeting sortilin seems to decrease GBM cell invasion, and could therefore be used in GBM therapy. Although further in vivo studies are needed, it should be noted that sortilin targeting in human cancers has recently entered a

[Wino115]

Great catch on your part, somehow I must have missed it when you posted. Let the Swedes mess with the BBB issues, THTX has their plate way full at this point.

[scarlet1967]

I didn't post here sometimes I send Christian various stuff, anything to do with NASH and oncology not only scientific studies but also regulatory etc. Hopefully the main message about much better communication and marketing is well received. His appearance at Rarecheck was a starter let's hope he and Paul do othe same attempts on more retail oriented platforms.

[Trogarzon]

How about Beliveau and Greespoon and Rottenberg among others... Beliveau is outstanding communicator.  The best CEO to market the company and by far was Andr De Villers and then Yves Rosconi.

[LouisW]

Did CMO comment on your information?

[scarlet1967]

No he didn't!